BWX Technologies, Inc. announced that its subsidiary BWXT Medical Ltd has executed a commercial agreement with Bayer AG to supply high-purity Actinium-225 (Ac-225).

The announcement follows the agreement reached by the two companies in September 2021. Under the terms of the commercial agreement, Bayer will purchase high-purity Ac-225 from BWXT Medical at pre-determined prices. The parties expect supply to commence later this year.

To read more please visit:

BWXT Medical Executes Commercial Agreement with Bayer for Supply of Actinium-225 Based Products

Source: BWXT